• Publications
  • Influence
Gallium in cancer treatment.
Gallium (Ga) is the second metal ion, after platinum, to be used in cancer treatment. Its activities are numerous and various. It modifies three-dimensional structure of DNA and inhibits itsExpand
  • 204
  • 9
  • PDF
Antitumour metal compounds: more than theme and variations.
Triggered by the resounding success of cisplatin, the past decades have seen tremendous efforts to produce clinically beneficial analogues. The recent achievement of oxaliplatin for the treatment ofExpand
  • 665
  • 8
Tumour-inhibiting platinum complexes--state of the art and future perspectives.
Thirty years after the onset of the first clinical studies with cisplatin, the development of antineoplastic platinum drugs continues to be a productive field of research. This article reviews theExpand
  • 333
  • 7
From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).
Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A) is just the second ruthenium-based anticancer agent after NAMI-A which was developed to the stage of clinical trials.Expand
  • 701
  • 6
Relevance of peat-draining rivers for the riverine input of dissolved iron into the ocean.
Peat bogs have the ability to produce strong chelate ligands (humic and fulvic acids) which enhance the weathering rates of iron-silicate minerals and greatly increase the solubility of the essentialExpand
  • 84
  • 6
Metal complexes in cancer chemotherapy
Metal complexes in cancer chemotherapy - general remarks, B.K. Keppler platinum an dnon-platinum complexes in clinical trials, M.E. Hein provisions for international approval of metal complexes inExpand
  • 445
  • 5
KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
The promising drug candidate indazolium trans‐[tetrachlorobis(1H‐indazole)ruthenate(III)] (KP1019) is the second Ru‐based anticancer agent to enter clinical trials. In this review, which is an updateExpand
  • 458
  • 5
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
NKP-1339 is the first-in-class ruthenium-based anticancer drug in clinical development against solid cancer and has recently been studied successfully in a phase I clinical trial. Ruthenium compoundsExpand
  • 320
  • 5
  • PDF
Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches.
Research in the field of bioinorganic chemistry has been stimulated by the worldwide success of the anticancer drug cisplatin. 40 years after the first report about its biological activity,Expand
  • 493
  • 4
Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation.
The first metal complexes of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine) were synthesized. Triapine was prepared by a novel three-step procedure in 64% overall yield. In addition, aExpand
  • 123
  • 4